BioLife Solutions (BLFS)
Supplies preservation media and cell-processing tools for cell and gene therapy workflows.
Something off on this page? Send us feedback.
Sells CryoStor, HypoThermosol, CellSeal, hPL products, and thawing tools used around cell and gene therapy manufacturing. After divesting freezer, biostorage, and logistics assets, the business is focused on recurring biopreservation and cell-processing products.
Provides biopreservation media and cell-processing tools used in cell and gene therapy manufacturing. Current lines include CryoStor and HypoThermosol media, BloodStor, CellSeal containers and fill-finish tools, hPL supplements, and ThawSTAR automated thawing devices.
Usage is tied to therapy developers that need cell integrity across collection, manufacturing, transport, storage, and final-dose handling. Evidence in context is strongest around U.S. clinical-trial use, while company materials frame the workflow as supporting global delivery.
Recent portfolio work moved away from freezer, biostorage, and logistics businesses toward recurring cell-processing consumables. Operations are managed as one reportable segment.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | Benchmark | Downgrade | ||
| Jul 27, 2026 | Stephens | Target | Target: $30 | Target: $31 |
| Jul 27, 2026 | Stephens & Co. | Downgrade | ||
| Jul 23, 2026 | Jefferies | Downgrade | Target: $22 | Target: $31 |
| Jul 23, 2026 | H.C. Wainwright | Downgrade | Target: $32 | Target: $31 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $82.4M · Total debt $15.7M · Total assets $447.5M · Shareholders' equity $420.0M
- Revenue
- $28.5M
- Operating income
- $1.7M
- Net income
- $45.1M
No dividends on record.
| Institutions | ≈ 101.33% | 49.56M shares | |
|---|---|---|---|
| 221 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.00% | 1.95M shares | |
| 13 holders · as of Sep 10, 2026 | |||
| Adds to | 105.33% | ||
48.91M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 105.33%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
T. Rowe Price Investment Management, Inc.Institution | 13.80% | 6.75M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 13.04% | 6.38M | as of Jun 30, 2026 |
Casdin Capital, LLCInstitution | 9.52% | 4.66M | as of Jun 30, 2026 |
Invesco Ltd.Institution | 4.58% | 2.24M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.02% | 1.96M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 21, 2026 | Casdin Partners Master Fund, L.P. | 10 percent owner | −650,000 | $23.70 |
| May 20, 2026 | Casdin Partners Master Fund, L.P. | 10 percent owner | −250,000 | $23.70 |
| May 19, 2026 | Casdin Partners Master Fund, L.P. | 10 percent owner | −300,000 | $22.65 |
| Mar 23, 2026 | Karen A. Foster | officer: Chief Quality and Operations | −2,577 | $19.17 |
| Mar 9, 2026 | Karen A. Foster | officer: Chief Quality and Operations | −500 | $20.00 |
- Thermo Fisher Scientific
Broad CGT media and automated cell-processing rival
- Danaher
Cytiva-led rival in integrated CGT processing platforms
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioLife Solutions | $37.90 | +1.92% | $1.82B | 36.3 | 187.1 | 17.7 | +12.0% |
| Thermo Fisher Scientific | $659.07 | +0.05% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Danaher | $221.03 | +2.40% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| Median | 36.9 | 25.1 | 5.7 | +8.0% |